Synopsis: Windlas Biotech Ltd reported a steady Q4 FY26 performance with healthy year-on-year revenue growth and stable profitability. The company also announced a dividend of Rs. 6.30 per equity share for FY26. Growth in pharmaceutical manufacturing demand, expanding...
SYNOPSIS: Multiple companies announced or planned share buybacks in April 2026, ranging from Rs. 470 crore to Rs. 15,000 crore, reflecting strong capital allocation strategies, shareholder returns focus, and management confidence across sectors. A share buyback is...
